Novartis faces pipeline pressure as Phase 3 DM1 drug misses primary endpoint
Novartis’ Phase 3 HARBOR trial for del-desiran in myotonic dystrophy type 1 failed to meet its primary endpoint, raising pipeline concerns.
Health
Read Full News
Internal Review of Diabetes Association Ejections Remains Open, Audit Panel Says
An audit panel says its probe into the June expulsions at the American Diabetes Association conference is incomplete and more findings are expected.
Readers Take the Mic: Letters Responding to Essays on MD vs. DO, AI and Surrogacy
STAT publishes selected Letters to the Editor responding to First Opinion essays on MD vs. DO, AI in medicine and surrogacy.
Sharp Drop in Overdose Deaths After Years of Rise, But Toll Remains High
After annual U.S. overdose deaths topped 105,000, 2024 saw a marked decline; preliminary 2025 figures and international drops signal change amid ongoing challenges.
Review Finds ADA Action Aimed at Conduct, Not Censoring Commentary
An internal ADA review says five-member expulsions followed conduct rules, not suppression of a Diabetes Care editorial; review sent to the board.
Updated Migraine Prevention Guidance Reflects Expanded Treatment Options
New joint guidance updates migraine prevention recommendations to reflect a broader range of therapies available since 2012.
FDA approves Mimrylo (rusfertide) as a new option for polycythemia vera
FDA clears rusfertide (Mimrylo) by Protagonist and Takeda as a weekly injection to treat polycythemia vera.
Novartis’ IL‑6 Antibody Lowers Inflammation in Phase 2 Trial, Raising Questions on Heart Benefit
Novartis’ IL‑6 antibody pacibekitug reduced inflammation biomarkers in a Phase 2 trial; experts await plans to test cardiovascular outcomes.
Kennedy and Pennsylvania Governor Clash as Measles Deaths Renew Focus on Vaccine Claims
Robert F. Kennedy Jr. and Governor Josh Shapiro exchanged heated words after two unvaccinated Pennsylvanians died of measles-related causes.
Sword Health Files to Buy Headspace in Move to Add Mental-Health Services
Sword Health filed to acquire Headspace; filing sets a Sept. 14 effective date and does not disclose the deal value.